Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment
NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer
The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide prostate cancer treatment, featuring talazoparib (...
Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable Healthcare
Sandoz's Strategic Momentum in Biosimilars and Generics
Sandoz's biosimilars strategy, as highlighted during the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlines its prog...
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
Pioneering Alzheimer's Care Innovation in Europe
Alzheimer's care innovation is transforming Europe's approach to the disease, shifting from policy discussions to real-world implementation of disease-modifying therapies. With 10 milli...